Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

and found more than 300 vials of counterfeit versions of semaglutide, tirzepatide — the ingredient in the weight loss drug Zepbound and the diabetes drug Mounjaro — along with other drugs ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

11,12 Effective step-up treatments in the setting of high-dose ICS+LABA therapy is an unmet need. A recently approved triple-therapy combination — fluticasone furoate, umeclidinium, and vilanterol ...

With costly medications or severe drug shortages encouraging the inappropriate reuse of single-dose vials, and a national survey in which 6% of nurses admitted to always or sometimes using this ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient ... gastrointestinal issues and other adverse effects after taking a 15-mg dose of tirzepatide. Many ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

Lilly, for its part, has resolved its Mounjaro and Zepbound shortages ... Lilly over the summer unveiled a steep discount to single-dose Zepbound vials through the company’s online LillyDirect ...

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...